Iodoniumsalz 3b | 68903-75-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: Iodoniumsalz 3b
• 英文别名: 3-iodo-4-phenoxy-1H-quinolin-2-one；3-iodo-4-phenoxy-1H-quinolin-2-one
• CAS: 68903-75-3
• 化学式: C₁₅H₁₀INO₂
• 分子量: 363.154
• InChiKey: QGQINRXPGQAWNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Iodoniumsalz 3b 、 溶剂黄146 以95%的产率得到
  参考文献：
  名称：

  KAPPE T.; KORBULY G.; STADTBAUER W., CHEM. BER., 1978, 111, NO 12, 3857-3866

  摘要：

  DOI：
• 作为产物：
  描述：

  2-Oxo-3-phenyliodonium-1,2-dihydrochinolin-4-olat 以70%的产率得到
  参考文献：
  名称：

  KAPPE T.; KORBULY G.; STADTBAUER W., CHEM. BER., 1978, 111, NO 12, 3857-3866

  摘要：

  DOI：

文献信息

• Pyridinone and pyridinethione derivatives having hiv inhibiting properties
  申请人：——

  公开号：US20040229847A1

  公开（公告）日：2004-11-18

  The present invention is concerned among others with compounds of formula (I), the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and stereochemically isomeric forms thereof, wherein Q is halo, C 1-6 alkyl or C 2-6 alkenyl; X is (a-2) with q and r being O and Z being O, S or SO; R 1 is aryl; R 2 is selected from formyl; C 1-6 alkyloxycarbonylalkyl; Het 2 ; Het 2 C 1-6 alkyl, C 1-6 alkylthio; C 1-6 alkyl optionally substituted with one or two substituents each independently selected from hydroxy, and halo; R 3 is selected from formyl; C 1-6 alkyl optionally substituted with one or two C 1-6 alkyloxy; R 1 is hydrogen, with HTV inhibiting properties. 1

  本发明涉及式(I)的化合物，其N-氧化物，药学上可接受的加成盐，季铵盐和立体化学异构体形式，其中Q是卤素，C1-6烷基或C2-6烯基; X为(a-2)，其中q和r为O，Z为O，S或SO; R1为芳基; R2选自甲酰基; C1-6烷氧羰基烷基; Het2; Het2C1-6烷基，C1-6烷基硫醚; C1-6烷基，可选用一个或两个取代基，独立地选自羟基和卤素; R3选自甲酰基; C1-6烷基，可选用一个或两个C1-6烷氧基; R1为氢，具有HTV抑制性能。
• 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS
  申请人：Tsou Hwei-Ru

  公开号：US20100068204A1

  公开（公告）日：2010-03-18

  Compounds of the formula I and pharmaceutically acceptable salts thereof, wherein A, B, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are defined as set forth herein are disclosed. Also disclosed are pharmaceutical compositions comprising the compounds of the invention and a pharmaceutically acceptable carrier, methods of making the compounds of the invention and methods of using the compounds for inhibiting mTOR and PI3 kinases and for treating cancers.

  本文披露了化学式I及其药学上可接受的盐的化合物，其中A、B、R1、R2、R3、R4、R5、R6和R7的定义如本文所述。本文还披露了包含本发明化合物和药学上可接受的载体的制药组合物，制备本发明化合物的方法以及使用本化合物抑制mTOR和PI3激酶并治疗癌症的方法。
• PYRIDINONE AND PYRIDINETHIONE DERIVATIVES HAVING HIV INHIBITING PROPERTIES
  申请人：CENTRE NATIONAL DELA RECHERCHE SCIENTIFIQUE (CNRS)

  公开号：EP1318995A2

  公开（公告）日：2003-06-18
• US7115608B2
  申请人：——

  公开号：US7115608B2

  公开（公告）日：2006-10-03
• [EN] PYRIDINONE AND PYRIDINETHIONE DERIVATIVES HAVING HIV INHIBITING PROPERTIES<br/>[FR] DERIVES DE PYRIDINONE ET DE PYRIDINETHIONE PRESENTANT DES PROPRIETES INHIBITRICES DU VIH
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2002024650A2

  公开（公告）日：2002-03-28

  The present invention is concerned among others with compounds of formula (1), the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and stereochemically isomeric forms thereof, wherein Q is halo, C1-6 alkyl or C2-6 alkenyl; X is (a-2) with q and r being O and Z being O, S or SO; R1 is aryl; R2 is selected from formyl; C1-6alkyloxycarbonylalkyl; Het?2; Het2C¿1-6alkyl, C1-6alkylthio; C1-6alkyl optionally substituted with one or two substituents each independently selected from hydroxy, and halo; R3 is selected from formyl; C1-6alkyl optionally substituted with one or two C1-6alkyloxy; R4 is hydrogen, with HIV inhibiting properties.